Back to News
Market Impact: 0.3
CHMP Backs Less Frequent Regeneron's Libtayo Dosing Across Approved Cancer Indications In Europe
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Regeneron said the EMA’s CHMP adopted a positive opinion recommending an updated Libtayo (cemiplimab) dosing regimen across all approved indications. The provided article text does not specify the dosing change or whether the recommendation has received final authorization.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
REGN0.55
More News
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- MSCI Ignites Indonesia Market Reckoning After Months of Warnings
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated